Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study

<p>Abstract</p> <p>Background</p> <p>Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting multiple scleros...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Stephenson Judith J, Kern David M, Agarwal Sonalee S, Zeidman Ruth, Rajagopalan Krithika, Kamat Siddhesh A, Foley John
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2012-12-01
Saila:Health and Quality of Life Outcomes
Gaiak:
Cognitive function
Health-related quality of life
Multiple sclerosis
Natalizumab
Patient-reported outcomes
Sarrera elektronikoa:http://www.hqlo.com/content/10/1/155
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak